Substance P enhances Th17 phenotype in individuals with generalized anxiety disorder: An event resistant to glucocorticoid inhibition

Journal of Clinical Immunology

Volumn 31, Issue 1, 2011, Pages 51-59

  Barros, Priscila O ^a   Ferreira, Thais B ^a   Vieira, Morgana M M ^a   Almeida, Carla Renata M ^a   Araújo Lima, Carlos Fernando ^a   Silva Filho, Renato G ^a   Hygino, Joana ^a   Andrade, Regis M ^a   Andrade, Arnaldo F ^b   Bento, Cleonice A ^a  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Generalized anxiety disorder; glucocorticoid; substance P; Th1 Th2; Th17

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION PROFILING; GENERALIZED ANXIETY DISORDER; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION;

ADOLESCENT; ADULT; ANXIETY DISORDERS; CELLS, CULTURED; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; PHENOTYPE; SUBSTANCE P; T-LYMPHOCYTES; TH17 CELLS; YOUNG ADULT;

EID: 79953837263     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9466-6     Document Type: Article

References (92)

1. Lazarczyk M, Matyja E, Lipkowski A. Substance P and its receptors - a potencial target for novel medicines in malignant brain tumour therapies (mini-review). Folia Neuropathol. 2007;45 (3):99-107. (Pubitemid 47520857)
2. O'Connor TM, O'Connell J, O'Brien D, Goode T, Bredin CP, Shanahan F. The role os substante P in inflammatory disease. J Cell Physiol. 2004;201:167-80.
3. Hokfelt T, Pernow B, Wahren J. Substance P: a Pioneer amongst neuropeptides. J Intern Med. 2001;249:27-40.
4. Zhang Y, Berger A, Milne CD, Paige CJ. Tachykinins in the immune system. Curr Drug Targets. 2006;7:1011-20. (Pubitemid 44227584)
5. Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol. 1998;86:80-6. (Pubitemid 28293952)
6. Marriott I, Bost KL. IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages. J Immunol. 2000;165:182-91. (Pubitemid 30429506)
7. Lighvani S, Huang X, Trivedi PP, Swanborg RH, Hazlett LD. Substance P regulates natural killer cell interferon-y production and resistance to Pseudomonas aeruginosa infection. Eur J Immunol. 2005;35:1567-75. (Pubitemid 40691437)
8. Laurenzi MA, Persson MA, Dalsgaard CJ, Haegerstrand A. The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide. Scand J Immunol. 1990;31:529-33. (Pubitemid 20121231)
9. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest. 2007;117:1119-25.
10. Crozat K, Vivier E, Dalod M. Crosstalk between components of the innate immune system: promoting anti-microbial defenses and avoiding immunopathologies. Immunol Rev. 2009;227:129-49.
11. Ekkens MJ, Liu Z, Liu Q, Whitmire J, Xiao S, et al. The role of OX40 ligand interactions in the development of the Th2 response to the gastrointestinal nematode parasiteHeligmosomoides polygyrus. J Immunol. 2003;170(1):384-93. (Pubitemid 36026163)
12. Wilson NJ, Boniface K, Chan JR, McKenzie B, Blumenschein WM, et al. de Waal Malefyt R: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-7. (Pubitemid 47300009)
13. Andoh A, Takaya H, Makino J, Sato H, Bamba S, et al. Cooperation of interleukin-17 and interferon-gamma on chemokine secretion in human fetal intestinal epithelial cells. Clin Exp Immunol. 2001;125:56-63. (Pubitemid 32703366)
14. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998;160:3513-21. (Pubitemid 28164746)
15. Matsuzaki G, Umemura M. IL-17 as an effetor molecule of innate and acquired immunity against infections. Microbiol Immunonol. 2007;51:1139-47.
16. Mathers AR, Tckacheva OA, Janelsins BM, Shufesky WJ, Morelli AE, Larregina AT. In vivo signaling through the neurokinin 1 receptor favors transgene expression by langerhans cells and promotes generation of Th1- and Tc1-biased immune responses. J Immunol. 2007;178:7006-17.
17. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human onocytes. Science. 1988;241:1218-21.
18. Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs. 2005;19:275-93. (Pubitemid 40593599)
19. Khouzam HR. Anxiety disorders: guidelines for effective primary care. Part 1: diagnosis. Consultant. 2009;49(3):1-3.
20. Boscarino JA. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. Ann N Y Acad Sci. 2004;1032:141-53. (Pubitemid 40298466)
21. Sareen J, Cox BJ, Clara I, Asmundson GJ. The relationship between anxiety disorders and physical disorders in the U.S. National Comorbidity Survey. Depress Anxiety. 2005;21:193-202.
22. Schneiderman N, Ironson G, Siegel SD. Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol. 2005;1:607-28. (Pubitemid 43843964)
23. Godbout JP, Glaser R. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. J Neuroimmune Pharm. 2006;1:421-7. (Pubitemid 44786675)
24. Arranz L, Guayerbas N, De la Fuente M. Impairment of several immune functions in anxious women. J Psychosom Res. 2007;62 (1):1-8. (Pubitemid 44937349)
25. Zhou FL, Zhang WG, Wei YC, Xu KL, Hui LY, et al. Impact of comorbid anxiety and depression on quality of life and cellular immunity changes in patients with digestive tract cancers. World J Gastroenterol. 2005;11(15):2313-8.
26. Koh KB, Lee Y. Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients. Psychother Psychosom. 2004;73(5):286-92. (Pubitemid 39060997)
27. Gill JM, Saligan L, Woods S, Page G. PTSD is associated with an excess of inflammatory immune activities. Perspect Psychiatr Care. 2009;45(4):262-77.
28. Wessa M, Rohleder N. Endocrine and inflammatory alterations inposttraumatic stress disorder. Expert Rev Endocrinol Metab. 2007;2:91-122.
29. Lemieux A, Coe CL, Carnes M. Symptom severity predicts degree of T cell activation in adult women following childhood maltreatment. Brain Behav Immun. 2008;22(6):994-1003.
30. Wilson S, van der Kolk B, Burbridge J, Fisler R, Kradin R. Phenotype of blood lymphocytes in PTSD suggests chronic immune activation. Psychosomatics. 1999;40:222-5. (Pubitemid 29232814)
31. Boscarino JA, Chang J. Higher abnormal leukocyte and lymphocyte counts 20 years after exposure to severe stress: research and clinical implications. Psychosom Med. 1999;61:378-86. (Pubitemid 29249797)
32. Cohen IR, Schwartz M. Autoimmune maintenance and neuroprotection of the central nervous system. J Neuroimmunol. 1999;100:111-4. (Pubitemid 30038244)
33. Affleck G, Urrows S, Tennen H, Higgins P, Pav D, Aloisi R. A dual pathway model of daily stressor effects on rheumatoid arthritis. Ann Behav Med. 1997;19:161-70. (Pubitemid 27400946)
34. Kohn PM, Kantor L, DeCicco TL, Beck AT. The beck anxiety inventory-trait (BAIT): a measure of dispositional anxiety not contaminated by dispositional depression. J Person Assessm. 2008;90:499-506.
35. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-5.
36. Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624-9.
37. Kang D, Davidson RJ, Coe CL, Wheeler RE, Tomarken AJ, Erschler WB. Frontal brain asymmetry and immune function. Behav Neurosc. 1991;105:860-9.
38. Lemieux AM, Coe CL. Abuse-related post-traumatic stress disorder: evidence of chronic neuroendocrine activation in women. Psychosom Med. 1995;57:105-15.
39. Strauman TJ, Lemieux AM, Coe CL. Self-discrepancies and natural killer cell activity: immunological consequences of negative self-evaluation. J Personal Soc Psychol. 1993;64:1042-52.
40. Strauman TJ, Woods TE, Schneider KL, Kwapil L, Coe CL. Self-regulatory cognition and immune reactivity: idiographic success and failure feedback effects on the natural killer cell. Brain Beh Imm. 1993;18:544-54.
41. Lang K, Drell TL, Niggemann B, Zanker KS, Entschladen F. Neurotransmitters regulate the migration and cytotoxicity in natural killer cells. Immunol Lett. 2003;2003(90):165-72. (Pubitemid 37548472)
42. Bastian P, Posch B, Lang K, Niggemann B, Zaenker KS, et al. Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes. Mol Cancer Res. 2006;4:411-21. (Pubitemid 44035160)
43. Bastian P, Balcarek A, Altanis C, Strell C, Niggemann B, et al. The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway. Cancer Lett. 2009;274:218-24.
44. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer. 2004;112:231-8. (Pubitemid 39244363)
45. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, et al. Inhibition of Th1 immune response by glucocorticoids: neurotransmitters selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol. 2000;164:1768-74. (Pubitemid 30108728)
46. Agarwal SK, Marshall GD. Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. J Interferon Cytokine Res. 1998;18:1059-68. (Pubitemid 29011614)
47. Lambrecht BN, Germonpre PR, Everaert EG, Carro-Muino I, De VeermanM, et al. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol. 1999;29:3815-25.
48. Nio DA, Moylan RN, Roche JK. Modulation of T lymphocyte function by neuropeptides: evidence for their role as local immunoregulatory elements. J Immunol. 1993;150:5281-8. (Pubitemid 23180641)
49. Takkouche B, Regueira C, Gestal-Otero JJ. A cohort study of stress and the common cold. Epidemiology. 2001;12:345-9. (Pubitemid 32336399)
50. Aviles H, Johnson MT, Monroy FP. Effects of cold stress on spleen cell proliferation and cytokine production during chronic Toxoplasma gondii infection. Neuroimmunomodulation. 2004;11 (2):93-102. (Pubitemid 38182777)
51. Cohen F, Kemeny ME, Kearney KA, Zegans LS, Neuhaus JM, Conant MA. Persistent stress as a predictor of genital herpes recurrence. Arch Intern Med. 1999;159:2430-6. (Pubitemid 29526771)
52. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and tress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun. 2003;17 Suppl 1:S27-36.
53. Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997;18:263-6. (Pubitemid 27261442)
54. Scholzen TE, Steinhoff M, Sindrilaru A, Schwarz A, Bunnett NW, et al. Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J. 2004;18:1007-9. (Pubitemid 39561507)
55. Akkoc T, de Koning PJ, Rückert B, Barlan I, Akdis M, Akdis CA. Increased activation-induced cell death of high IFN-gammaproducing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. J Allergy Clin Immunol. 2008;121(3):652-8.
56. O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci. 2009;29:4200-9.
57. Dai H, Daí Z. The role of tryptophan catabolism in acquisition and effector function of memory T cells. Cur Opin Organ Transpl. 2008;13:31-5.
58. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000;23:477-501.
59. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160:1-12. (Pubitemid 29044562)
60. Poliak S, Mor F, Conlon P, Wong T, Ling N, et al. Stress and autoimmunity: the neuropeptides corticotrophin releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary- adrenal axis the immune system. J Immunol. 1997;158:5751-6. (Pubitemid 127483980)
61. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000;18:309.
62. TohMC, KawashimaM, Zrioual S, Hot A,Miossec P. IL-17 inhibits human Th17 differentiation through IL-12 beta 2 downregulation. Cytokine. 2009;48:226-30.
63. Newcomb DC, Zhou W, Moore ML, Goleniewska K, Hershey GK, et al. A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol. 2009;182:5317-21.
64. CostantinoCM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol. 2008;38:921-4.
65. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523-32.
66. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3-precursor cells in the absence of interleukin 10. Nat Immunol. 2007;8:931-41. (Pubitemid 47300007)
67. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med. 2003;198:1179-88. (Pubitemid 37323383)
68. Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30:636-45.
69. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7:875-88. (Pubitemid 350006238)
70. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory T cells within the central nervous system. J Immunol. 2005;175:3025-32. (Pubitemid 41170521)
71. Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-b and interleukin-10. Immunity. 2008;8:468-76. (Pubitemid 351467045)
72. De Kloet CS, Vermetten E, Geuze E, Kavelaars E, Heijnen A, Westenberg CJ. Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. J Psychiatry Res. 2006;40(6):550-67. (Pubitemid 44175408)
73. Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett. 2007;114:1-8.
74. Davidson TS, DiPaolo RJ, Andersson J, Shevach EM. Cutting edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3 + T regulatory cells. J Immunol. 2007;178:4022-6. (Pubitemid 46492349)
75. Horwitz DA, Zheng SG, Wang J, Gray JD. Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3+ CD4+ Treg. Eur J Immunol. 2008;38:912-5.
76. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008;29:44-56.
77. Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, et al. DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol. 2008;38:3274-81.
78. Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erytematosus: current concepts. Clin Exp Immunol. 2009;157(2):209-15.
79. Di Cesare A, Di Meglio P, Nestle PD. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129 (6):1339-50.
80. Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008;255 (S6):2-6.
81. Liu ZJ, Yadav PK, Su JL, Wang JS, Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009;15(46):5784-8.
82. von Känel R, Hepp U, Kraemer B, Traber R, Keel M, et al. Evidence for low-grade systemic proinflammatory activity in individuals with posttraumatic stress disorder. J Psych Res. 2007;41:744-52. (Pubitemid 46659723)
83. Muller N, Schwarz MJ. Immunology in anxiety and depression. In: Kasper S, den Boer JA, Sitsen JMA, editors. Handbook of depression and anxiety. New York: Marcel Dekker; 2002. p. 267-88.
84. Sutherland AG, Alexander DA, Hutchison JD. Disturbance of pro-inflammatory cytokines in post-traumatic psychopathology. Cytokine. 2003;24:219-25. (Pubitemid 37330124)
85. Gill JM, Vythilingam M, Page G. Low cortisol, high DHEA, and high levels of TNF-a and IL-6 in women with PTSD. J Traum Stress. 2008;21(6):530-9.
86. Siebenhaar F, Sharo AA, Peters EMJ, Sharova TY, Syska W, Mardarye AN, et al. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (Alopecia Areata). J Investig Dermatol. 2007;127:1489-97. (Pubitemid 46766534)
87. Hordinsky M, Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc. 2004;9:73-8.
88. Tuncer LI, Alacam T, Oral B. Substance P expression is elevated in inflamed human periradicular tissue. J Endod. 2004;30:329-32. (Pubitemid 38658282)
89. Felten DL, Felten SY, Bellinger DL, Lorton D. Noradrenergic and peptidergic innervation of secondary lymphoid organs: role in experimental rheumatoid arthritis. Eur J Clin Invest. 1992;22 Suppl 1:37-41.
90. Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann NY Acad Sci. 2006;1069:62-76. (Pubitemid 43989851)
91. Grimsholm O, Rantapää-Dahlqvist S, Dalén T, Forsgren S. Observations favouring the occurrence of local production and marked effects of bombesin/gastrin-releasing peptide in the synovial tissue of the human knee joint - comparisons with substance P and the NK-1 receptor. Neuropeptides. 2008;42 (2):133-45.
92. Rösler N, Reuner C, Geiger J, Rissler K, Cramer H. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease. Peptides. 1990;11(1):181-3. (Pubitemid 20073482)